
Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Altimmune securities between August 10, 2023, and June 25, 2025, with a deadline of October 6, 2025, for investors to apply as lead plaintiffs [1]. - The complaint highlights that Altimmune's announcement on June 26, 2025, revealed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction in the trial, despite prior inflated expectations [3]. Group 2: Stock Price Impact - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [4].